AlphaStocks
4.2
Weak

Arcus Biosciences, Inc. (RCUS)

As of Sep 20, 2026, Arcus Biosciences, Inc. (RCUS) scores 4.2/10 on AlphaStocks' five-model composite, #134 of 168 Health Care stocks.

Health Care / Biotechnology

S&P SmallCap 600

$25.23

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#134out of 168 in Health Care

Is Arcus Biosciences, Inc. a Good Investment in 2026?

Arcus Biosciences, Inc. (RCUS) scores 4.2 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Graham model is the most favorable, rating Arcus Biosciences, Inc. as Neutral. However, the Greenblatt Magic Formula model rates it Caution — Earnings yield -12.9% · ROC -47%. Arcus Biosciences, Inc. ranks #134 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-18.0Market Cap3B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Caution

1/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield -12.9% · ROC -47%

Frequently Asked Questions

Is Arcus Biosciences, Inc. (RCUS) a good investment?
As of Sep 20, 2026, Arcus Biosciences, Inc. (RCUS) scores 4.2/10 on AlphaStocks' five-model composite, #134 of 168 Health Care stocks. That score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Arcus Biosciences, Inc.'s Piotroski F-Score?
Arcus Biosciences, Inc.'s Piotroski F-Score status is Caution. The raw score is 1/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is RCUS overvalued or undervalued?
A precise fair value estimate is not available for RCUS. Currently unprofitable — fair value estimate not available.
How does RCUS compare to other Health Care stocks?
Arcus Biosciences, Inc. ranks #134 out of 168 stocks in the Health Care sector, placing it in the top 80% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about RCUS?
AlphaStocks evaluates RCUS using five proven investment models. Piotroski: Caution; Buffett: Caution; Graham: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.2/10.

Similar Stocks

ABBVINCYHRMY

Compare RCUS with

ABBV vs RCUSINCY vs RCUSHRMY vs RCUS

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer